PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse

JTI by 2FIRSTS, edited by Sophia
Apr.09.2024
PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
PMI launches VEEV vape brand in Germany, competing with Vuse from China and BAT, targeting tobacco users.

According to the German media Nouvelles, Philip Morris International (PMI) has decided to launch its vape brand VEEV in Germany, thereby competing with major Chinese manufacturers as well as the rival product Vuse from British American Tobacco (BAT). Although PMI had already included e-cigarettes in its product line several years ago and sold them in other countries such as Poland, the Czech Republic, and Greece, it had never sold e-cigarettes in Germany.

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Disposable product VEEV NOW | Image source: PMI

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Pod-system product VEEV ONE | Image source: PMi

 

PMI's Chief Spokesperson, Torsten Albig, stated in a media interview, "We have made extensive and intensive efforts at the government level to ban the sale of disposable e-cigarettes, but to no avail. Therefore, we have decided to enter this market as well."

 

Among teenagers and young people, disposable e-cigarettes are particularly popular. However, the German Federal Ministry of Food and Agriculture appears to be considering banning the use of mint as an ingredient in e-cigarettes in order to reduce the possibility of e-cigarettes gaining market share. However, policymakers in other European countries have responded more uniformly to this issue. For example, countries like France and Belgium will ban the sale of disposable e-cigarettes starting next year.

 

PMI is planning to launch a rechargeable e-cigarette while also selling disposable products. "But this should only be a test product," Albig explained.

 

PMI's current sales policy is to offer a free VEEV charging device with the purchase of three disposable e-cigarettes. This promotion is taking place at participating retailers and the company's IQOS stores. Altria announced that VEEV will be introduced in stores located in major cities that previously only sold heated tobacco products.

 

However, he also admitted that the introduction of e-cigarettes is not just a response to policy loopholes.

 

He pointed out:

 

If we want to achieve our global goals as a group and have over two-thirds of our net revenue contributed by tobacco alternatives by 2030, we cannot afford to leave the German market.

 

In this country, PMI and its IQOS heated tobacco products only occupy a market share of 6%, slightly higher in major cities at just over 10%. Meanwhile, their Marlboro cigarettes hold a 25% market share.

 

PMI hopes to attract smokers with the e-cigarette VEEV and provide competitive pricing: the disposable version will be sold for 7.90 euros, while two refill pods for the reusable system will be priced at 8.90 euros.

 

Although competitors' disposable e-cigarettes are generally priced at ten euros or higher, PMI has decided to challenge their position. Alberg remains calm about the ban on using mint or flavorings in e-cigarettes. He said, "If that's how it is, then so be it. Our products are not meant to attract young people, but to satisfy cigarette smokers who are already accustomed to the taste of tobacco.

 

The World Health Organization has clearly stated that alternative tobacco products are not healthier than traditional tobacco. At the same time, scientists who receive funding from the tobacco industry for research are often suspected of lobbying for the tobacco industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
According to Interfax-Ukraine, a study conducted by market research firm Kantar Ukraine at the request of major tobacco companies found that more than 93% of vape products in Ukraine did not fully comply with regulatory requirements. The research examined product categories, brand distribution and consumer purchasing channels, showing that pod systems and disposable vapes represent major segments of the market, while offline retail remains the dominant purchasing channel. The findings highlight ongoing compliance challenges in Ukraine’s vape market.
Aug.26
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24